GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Amedisys Inc (NAS:AMED) » Definitions » Operating Income
中文

Amedisys (Amedisys) Operating Income

: $173 Mil (TTM As of Dec. 2023)
View and export this data going back to 1994. Start your Free Trial

Amedisys's Operating Income for the three months ended in Dec. 2023 was $46 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $173 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Amedisys's Operating Income for the three months ended in Dec. 2023 was $46 Mil. Amedisys's Revenue for the three months ended in Dec. 2023 was $571 Mil. Therefore, Amedisys's Operating Margin % for the quarter that ended in Dec. 2023 was 7.98%.

Warning Sign:

Amedisys Inc operating margin has been in a 5-year decline. The average rate of decline per year is -1.8%.

Amedisys's 5-Year average Growth Rate for Operating Margin % was -1.80% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Amedisys's annualized ROC % for the quarter that ended in Dec. 2023 was 7.22%. Amedisys's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 99.80%.


Amedisys Operating Income Historical Data

The historical data trend for Amedisys's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amedisys Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 178.94 223.42 251.92 183.78 193.07

Amedisys Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.24 42.38 37.80 47.19 45.53

Amedisys Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $173 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amedisys  (NAS:AMED) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Amedisys's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=182.12 * ( 1 - 34.86% )/( (1621.665 + 1663.884)/ 2 )
=118.632968/1642.7745
=7.22 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2027.417 - 406.644 - ( 78.112 - max(0, 468.119 - 467.227+78.112))
=1621.665

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2060.17 - 373.072 - ( 126.45 - max(0, 473.721 - 496.935+126.45))
=1663.884

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Amedisys's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=149.728/( ( (127.465 + max(-17.529, 0)) + (172.584 + max(-62.436, 0)) )/ 2 )
=149.728/( ( 127.465 + 172.584 )/ 2 )
=149.728/150.0245
=99.80 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(319.58 + 0 + 69.535) - (406.644 + 0 + 0)
=-17.529

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(313.373 + 0 + 35.312) - (373.072 + 0 + 38.049)
=-62.436

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Amedisys's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=45.53/570.788
=7.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Amedisys Operating Income Related Terms

Thank you for viewing the detailed overview of Amedisys's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Amedisys (Amedisys) Business Description

Traded in Other Exchanges
Address
3854 American Way, Suite A, Baton Rouge, LA, USA, 70816
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
Executives
Allyson Guidroz officer: Chief Accounting Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard M Ashworth director, officer: President and CEO 200 WILMOT ROAD, DEERFIELD IL 60015
Michael Paul North officer: Chief Information Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Adam Y Holton officer: Chief People Officer C/O CHS INC., 5500 CENEX DRIVE, INVER GROVE HEIGHTS MN 55077
Denise M. Bohnert officer: Chief Compliance Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Nick Muscato officer: Chief Strategy Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard A Lechleiter director PO BOX 32890, LOUISVILLE KY 40232-2890
Bruce D Perkins director 500 WEST MAIN STREET, LOUISVILLE KY 40202
Christopher Gerard officer: Chief Operating Officer 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Teresa L. Kline director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeffrey A Rideout director 2142 DEER OAK WAY, DANVILLE CA 94506
Julie D Klapstein director 1239 FRUIT COVE ROAD NORTH, JACKSONVILLE FL 32259
Molly Joel Coye director AETNA INC, 151 FARMINGTON AVENUE, HARTFORD CT 06156
David L Kemmerly officer: See Remarks 3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816